| Literature DB >> 26563141 |
Jean-Ralph Zahar1,2, Laurent Poirel3,4, Claire Dupont5, Nicolas Fortineau6, Xavier Nassif7, Patrice Nordmann8,9,10.
Abstract
BACKGROUND: Extended-spectrum β-lactamases producing Escherichia coli (ESBL-E) are increasingly identified in health care facilities. As previously done for the control of methicillin-resistant Staphylococcus aureus, many hospitals have established screening strategies for early identification of patients being carriers of ESBL producers in general and ESBL-E in particular, and have implemented contact precautions (CP) for infected and colonized patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26563141 PMCID: PMC4642679 DOI: 10.1186/s12879-015-1244-x
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Features related to isolation of ESBL-producing Enterobacteriaceae in both hospitals during the Jan 2006 – Sept 2010 period
| Features | Hospital A | Hospital B |
|
|---|---|---|---|
| Median age (Q1-Q3), | 9 (2–52), | 61 (45–74), | <0.0001* |
| Gender | |||
| Men | 53.9 %, | 51.9 %, | 0.5 |
| Women | |||
| Hospitalization unit (%), | |||
| Medicine | 53.4 %, | 41.1 %, | <0.0001* |
| Surgery | 33.1 %, | 27.7 %, | without |
| ICU | 13.5 %, | 31.1 %, | ICU |
| Clinical site (%), n | 0.54** | ||
| Urine | 60.5 %, | 59.9 %, | <0.0001* |
| Blood culture | 10.2 %, | 9.1 %, | without |
| Respiratory no protected | 10.2 %, | 3.3 %, | respiratory |
| Respiratory protected | 3.8 %, | 4.1 %, | no protected |
| Intravascular devices | 4.7 %, | 6.4 %, | 0.07** |
| Deep purulent samples | 1.8 %, | 4.1 %, | |
| Others | 8.8 %, | 13.1 %, | |
| ESBL-producing Enterobacteriaceae by species (%), | |||
|
| 38.7 %, | 44.6 %, | 0.0033* |
|
| 15.4 %, | 19.3 %, | without |
|
| 37.5 %, | 27.5 %, | 0.73** |
| Other ESBL producers | 8.4 %, | 8.7 %, |
* p < 0.05, or ** p > 0.05 after deleting the varying category between hospital; Kolmogorov-Smirnov and Chi2 Test
Fig. 1Respective quarterly ESBL-producing E. coli incidences in hospitals A and B; January 1st, 2006 to September 30th, 2010
Fig 2Respective quarterly ESBL-producing K. pneumoniae and E. cloacae incidences in hospitals A and B; January 1st, 2006 to September 30th, 2010
ESBL-producing Enterobacteriaceae, isolated time (IT) by species, and considered variablesa
| Median KS test (Q1-Q3), | ||||||
|---|---|---|---|---|---|---|
| Median IT with 1st and 3rd quartiles and Kolmogorov-Smirnov (KS) test | ESBL-positive | ESBL-positive | ESBL-positive | |||
| Number of isolates (total = 1078) | ||||||
| Hospital A | 1.5 (0–9), | 8.5 (2–23), | 8 (1–23), | |||
|
|
|
| ||||
| Hospital B | 3 (0–13), | 17 (7–31), | 13 (3–28), | |||
| Unit’s activity ( | ||||||
| Medicine (reference) | 2 (0–8), | 10.5 (2–31), | 8 (1–23), | |||
| Surgery | 2.5 (0–14), |
| 13 (5–24), |
| 7 (1–17), |
|
| ICU | 5 (1.5–13.5), |
| 15 (7.5–28.5), |
| 17.5 (7.5–37), |
|
| Age ( | ||||||
| Children (<14 y-old) | 2.5 (0–9.5), | 7 (1–22), | 8 (2–26.5), | |||
|
|
|
| ||||
| Adult | 2 (0–11), | 14 (6–27), | 11 (1–24), | |||
| Gender ( | ||||||
| Men | 4 (0–15), | 14 (5–28.5), | 10 (1–24), | |||
|
|
|
| ||||
| Women | 2 (0–8), | 14 (5–27), | 9 (1–25.5), | |||
| Clinical site ( | ||||||
| Urine (reference) | 2 (0–10.5), | 14 (4–28.5), | 8 (1–23), | |||
| Blood culture | 2 (0–7), |
| 15.5 (5–28), |
| 11 (1–28), |
|
| Respiratory protected | 5 (1–14), |
| 12 (5.5–24), |
| 19 (5–62), |
|
| Respiratory unprotected | 2 (1–7), |
| 13 (2–26), |
| 8.5 (3–21), |
|
| Intravascular devices | 8 (4–9), |
| 14 (7–25), |
| 14 (9–21), |
|
| Deep purulent samples | 17 (1–41), |
| 18 (4–27), |
| 19 (14–21), |
|
| Total by ESBL producer | 2 (0–11), | 14 (5–28), | 10 (1–24), | |||
aTotal numbers may differ according to categories since some data were not always available; bsignificant level, p < 0.05